

HPMS E-Mail
Tuesday, May 31, 2022

Subject: FDA Educational Message for Providers

Below is a provider education message from the FDA regarding interchangeable biosimilars.

Biosimilars: Interchangeable Products May Increase Patient Access

Depending on state pharmacy laws, you may substitute an interchangeable biosimilar product at the pharmacy, much like substituting a generic for a brand-name drug. This helps increase patient access to biologics and may reduce patient costs. Learn more about [Interchangeable Biological Products](#) from the FDA. Bookmark FDA's [Biosimilars](#) webpage and materials for [health care providers](#) and [patients](#).

Additional FDA resources you may find helpful:

- [Overview of Biosimilar Products](#)
- [Biosimilar Regulatory Review and Approval \(PDF\)](#)